Biogen Pharmaceuticals

Biogen is a global biotechnology leader focused on developing therapies for people living with serious neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has pioneered treatments for multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer’s disease. Its current commercial portfolio includes Leqembi for Alzheimer's, Spinraza for SMA, and a leading suite of MS therapies such as Tysabri and Tecfidera. Biogen continues to advance a diverse pipeline targeting amyotrophic lateral sclerosis (ALS), lupus, and Parkinson’s disease. Through strategic acquisitions like Reata Pharmaceuticals and partnerships with companies like Eisai and Ionis, Biogen remains at the forefront of neuroscience innovation.